7 月 3 日,NMPA 官网显示,礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究,Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报,扫描文末二维码添加小音,即可免费下载。截图来源:NMPA 官网替尔泊肽(Tirzepatide,穆峰达®)是代谢领域的重磅炸弹药物。...
Source Link7 月 3 日,NMPA 官网显示,礼来制药GLP-1R/GIPR 双重激动剂“替尔泊肽”新适应症在华获批上市。根据公开资料及既往临床研究,Insight 数据库推测此次获批适应症为治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。*如需获取 2025 年更多新药获批情报,扫描文末二维码添加小音,即可免费下载。截图来源:NMPA 官网替尔泊肽(Tirzepatide,穆峰达®)是代谢领域的重磅炸弹药物。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.